Skip to main content

Advertisement

Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Fig. 5

Effects of M802 on cancer-related signaling pathways. Cells were treated with M802 or Herceptin, and then harvested and subjected to western blotting for detection of Akt, p-Akt, Erk, and p-Erk after 24 h, and detection of cyclin D1, P21, P27, caspase-3, and cleaved-caspase-3 after 48 h. β-actin was used as the internal reference, and 3 independent replicates were performed

Back to article page